Urotensin II and cardiovascular diseases

被引:37
|
作者
Thanassoulis, G [1 ]
Huyhn, T [1 ]
Giaid, A [1 ]
机构
[1] McGill Univ, Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada
关键词
vascular physiology; atherosclerosis; coronary artery disease; heart failure; metabolic syndrome;
D O I
10.1016/j.peptides.2004.05.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urotensin II (UII) has been found to be a potent vasoactive peptide in humans and in a number of relevant animal models of cardiovascular disease such as the mouse, rat and other non-human primates. This peptide with structural homology to somatostatin was first isolated from the urophysis of fish and was recently found to bind to an orphan receptor in mouse and human. Initially found to have potent vasoconstrictive activities in a variety of vessels from diverse species, it has also been shown to exert vasodilatation in certain vessels in the rat and human by various endothelium-dependent mechanisms. The various vasoactive properties of UII suggest that the peptide may have a physiological role in maintaining vascular tone and therefore may have a role in the pathophysiology of a number of human diseases such as heart failure. Moreover, UII has also been implicated as a mitogen of vascular smooth muscle cells suggesting a deleterious role in atherosclerosis and coronary artery disease. In addition, there is evidence to demonstrate that UII has multiple metabolic effects on cholesterol metabolism, glycemic control and hypertension and therefore may be implicated in the development of insulin resistance and the metabolic syndrome. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1789 / 1794
页数:6
相关论文
共 50 条
  • [31] The significance of urotensin II, a new vasoactive peptide, in the pathophysiology of kidney diseases
    Satoh, F
    Arima, S
    Kohagura, K
    Abe, T
    Totsune, K
    Takeuchi, K
    Ito, S
    JOURNAL OF HYPERTENSION, 2002, 20 : S124 - S124
  • [32] Urotensin II, urotensin II-related peptide and their receptors
    Vaudry, Hubert
    PEPTIDES, 2008, 29 (05) : 647 - 648
  • [33] METFORMIN MAY INHIBIT CARDIOVASCULAR REMODELING THROUGH SUPPRESSING UROTENSIN II AND ANGIOTENSIN II SYSTEM
    Song, Nana
    Ding, Wenhui
    Guo, Xiaohui
    Li, Kang
    Yu, Zongdong
    HEART, 2011, 97
  • [34] Superoxide mediates central cardiovascular effects of Urotensin II in spontaneously hypertensive rats
    Lu, Ning
    Zhou, Li
    Yao, Tai
    Zhu, Yi-chun
    FASEB JOURNAL, 2008, 22
  • [35] Urotensin-II protects against cardiovascular events in patients with kidney disease
    不详
    Nature Clinical Practice Nephrology, 2006, 2 (7): : 350 - 350
  • [36] Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?
    Demirpence, M.
    Guler, A.
    Yilmaz, H.
    Sayin, A.
    Pekcevik, Y.
    Turkon, H.
    Colak, A.
    Ari, E. M.
    Aslanipour, B.
    Kocabas, G. U.
    Calan, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (02) : 207 - 215
  • [37] Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates
    Conlon, JM
    Yano, K
    Waugh, D
    Hazon, N
    JOURNAL OF EXPERIMENTAL ZOOLOGY, 1996, 275 (2-3): : 226 - 238
  • [38] CARDIOVASCULAR ACTIONS OF DOGFISH UROTENSIN-II IN THE DOGFISH SCYLIORHINUS-CANICULA
    HAZON, N
    BJENNING, C
    CONLON, JM
    AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (03): : R573 - R576
  • [39] Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II
    Strack, Martin
    Billard, Etienne
    Chatenet, David
    Lubell, William D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (15) : 3412 - 3416
  • [40] Urotensin II: a cardiovascular and renal update (vol 17, pg 199, 2008)
    Zoccali, C.
    Mallamaci, F.
    Urotensin, I. I.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (05):